> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Office of New Drugs Name Changes
- URL: https://www.fdaweb.com/office-of-new-drugs-name-changes/
- Published: 2020-01-21T12:00:00.000Z
- Updated: 2026-09-14T15:59:22.000Z
- Author: David McFarland
- Tags: Drugs, FDA Policy/General, Devices, #legacy-id-D5145893

CDER says that the approved restructuring of the Office of New Drugs (OND) created offices that align interrelated disease areas and divisions with clearer and more focused areas of expertise. As a result, an online [notice](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/applications-affected-reorganization-office-new-drugs?ref=fdaweb.com) says, the names of the OND offices and divisions have changed. CDER says sponsors will be notified if there is a change in signatory or point of contact for applications currently under review. The notice gives start dates for each phase of the reorganization.